CDEK
← All drugs Report issue

tak-881

Recombinant proteinexperimental

Clinical trial activity

7 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
3
Phase 2
2
Phase 3
3
Phase 4
0

Earliest trial started Oct 6, 2021 (NCT05059977)

Timeline

2020s

  1. Jan 1, 2021

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2023

    Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2024

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06935266Phase 1Apr 22, 2025Takeda
NCT06747351Phase 3Apr 1, 2025Takeda
NCT06895967Phase 1Mar 24, 2025Takeda
NCT06076642Phase 3Dec 6, 2024Takeda
NCT05755035Phase 2/Phase 3 (Phase 3)Oct 24, 2023Takeda
NCT05059977Phase 1Oct 6, 2021Shire, Takeda
NCT06955793N/A—Takeda
Showing 7 of 7 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
TakedaFor profit7732021
ShireFor profit1012021
2 organizations
Page 1 / 1